439 related articles for article (PubMed ID: 29478946)
1. Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American Center.
Jaime-Pérez JC; Padilla-Medina JR; Fernández LT; Herrera-Garza JL; Gutiérrez-Aguirre CH; Tarín-Arzaga L; Gómez-Almaguer D
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):286-292. PubMed ID: 29478946
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia.
Nasir SS; Giri S; Nunnery S; Martin MG
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):126-132.e1. PubMed ID: 27836483
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and clinical evolution of patients with acute myeloblastic leukemia in northeast Mexico: an eight-year experience at a university hospital.
Jaime-Pérez JC; Brito-Ramirez AS; Pinzon-Uresti MA; Gutiérrez-Aguirre H; Cantú-Rodríguez OG; Herrera-Garza JL; Gomez-Almaguer D
Acta Haematol; 2014; 132(2):144-51. PubMed ID: 24556725
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.
Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K
Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia.
Tomizawa D; Tanaka S; Kondo T; Hashii Y; Arai Y; Kudo K; Taga T; Fukuda T; Goto H; Inagaki J; Koh K; Ohashi K; Ozawa Y; Inoue M; Kato K; Tanaka J; Atsuta Y; Adachi S; Ishida H
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1515-1522. PubMed ID: 28501543
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Childhood Acute Myeloid Leukemia in Bulgaria.
Burnusuzov HA; Yordanova MN; Avramova BE; Yurukova NN; Bachvarov KN; Muchinova AB; Vlahova IH; Stoyanova AA; Mumdzhiev IN; Ivanova LR; Spasov NY; Peteva ET; Belcheva MI; Hristozova H; Spasova MI; Kaleva VI; Bobev D; Konstantinov DN
Folia Med (Plovdiv); 2018 Jun; 60(2):234-240. PubMed ID: 30355812
[TBL] [Abstract][Full Text] [Related]
8. Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial.
Quarello P; Fagioli F; Basso G; Putti MC; Berger M; Luciani M; Rizzari C; Menna G; Masetti R; Locatelli F
Br J Haematol; 2015 Nov; 171(4):566-73. PubMed ID: 26223157
[TBL] [Abstract][Full Text] [Related]
9. Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience.
Kairiene I; Pasauliene R; Lipunova N; Vaitkeviciene G; Rageliene L; Rascon J
Eur J Pediatr; 2017 Oct; 176(10):1329-1337. PubMed ID: 28812191
[TBL] [Abstract][Full Text] [Related]
10. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
Lins MM; Mello MJG; Ribeiro RC; De Camargo B; de Fátima Pessoa Militão de Albuquerque M; Thuler LCS
Ann Hematol; 2019 Jun; 98(6):1403-1411. PubMed ID: 30915498
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of Australian adolescents and young adults with acute lymphoblastic and myeloid leukemias: A national population-based study.
White VM; Skaczkowski G; Pinkerton R; Coory M; Osborn M; Bibby H; Nicholls W; Orme LM; Conyers R; Phillips MB; Harrup R; Walker R; Thompson K; Anazodo A
Pediatr Blood Cancer; 2018 Nov; 65(11):e27349. PubMed ID: 30039912
[TBL] [Abstract][Full Text] [Related]
12. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
13. Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma.
Kahn JM; Keegan TH; Tao L; Abrahão R; Bleyer A; Viny AD
Cancer; 2016 Sep; 122(17):2723-30. PubMed ID: 27286322
[TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
15. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
[TBL] [Abstract][Full Text] [Related]
16. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
17. [A long-term follow-up study of 82 children with acute myeloid leukemia].
Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
[No Abstract] [Full Text] [Related]
18. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
Fang J; Zhang R; Wang H; Hong M; Wu Q; Nie D; You Y; Zhong Z; Li W; Hu Y; Xia L
Leuk Res; 2016 Jul; 46():61-8. PubMed ID: 27131062
[TBL] [Abstract][Full Text] [Related]
19. Results of Treating Childhood Acute Lymphoblastic Leukemia in a Low-middle Income Country: 10 Year Experience in Northeast Mexico.
Jaime-Pérez JC; López-Razo ON; García-Arellano G; Pinzón-Uresti MA; Jiménez-Castillo RA; González-Llano O; Gómez-Almaguer D
Arch Med Res; 2016 Nov; 47(8):668-676. PubMed ID: 28476194
[TBL] [Abstract][Full Text] [Related]
20. Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes.
Lalayanni C; Demosthenous C; Iskas M; Kelaidi C; Papathanasiou M; Syrigou A; Athanasiadou A; Papalexandri A; Batsis I; Vardi A; Polychronopoulou S; Sakellari I
Leuk Lymphoma; 2022 Dec; 63(13):3128-3137. PubMed ID: 36002396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
